Azactam and Haldol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Azactam (aztreonam) and Haldol (haloperidol). Common drug interactions include renal failure among females and eosinophilia among males.

The phase IV clinical study analyzes what interactions people have when they take Azactam and Haldol. It is created by eHealthMe based on reports of 31 people who take the same drugs from the FDA, and is updated regularly.

What is Azactam?

Azactam has active ingredients of aztreonam. eHealthMe is studying from 1,044 Azactam users. Check the latest studies of Azactam.

What is Haldol?

Haldol has active ingredients of haloperidol. It is often used in schizophrenia. eHealthMe is studying from 23,102 Haldol users. Check the latest studies of Haldol.

On Aug, 11, 2026

31 people who take Azactam and Haldol together, and have interactions are studied.

What are the common drug interactions of Azactam and Haldol, by gender? *:

female:

Renal failure (kidney dysfunction)
Pneumonia
Respiratory failure (inadequate gas exchange by the respiratory system)
Cardiac disorder
Chronic kidney disease
Coma (state of unconsciousness lasting more than six hours)
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Empyema (collection of pus in a cavity in the body)
Eosinophilia (eosinophil count in the peripheral blood exceeds)
Gastrointestinal necrosis (destruction of gastrointestinal organ)

male:

Eosinophilia (eosinophil count in the peripheral blood exceeds)
Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)
Anxiety
Attention deficit/hyperactivity disorder
Cardiogenic shock (inadequate circulation of blood)
Chest pain
Coma (state of unconsciousness lasting more than six hours)
Dyspnoea (difficult or laboured respiration)
Energy increased
Haemorrhagic stroke (stroke caused by the rupture of a blood vessel in the brain)

What are the common drug interactions of Azactam and Haldol, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Coma (state of unconsciousness lasting more than six hours)
Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function)
Liver transplant
Overdose
Renal failure (kidney dysfunction)
Suicide attempt

20-29:

n/a

30-39:

n/a

40-49:

Eosinophilia (eosinophil count in the peripheral blood exceeds)
Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)
Circulatory collapse
Rash generalised (rash on most of body parts)
Rash
Vasoplegia syndrome (low systemic vascular resistance)
Cardiogenic shock (inadequate circulation of blood)
Chest pain
Dyspnoea (difficult or laboured respiration)
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)

50-59:

Pneumonia
Respiratory failure (inadequate gas exchange by the respiratory system)
Chronic kidney disease
Empyema (collection of pus in a cavity in the body)
Osteomyelitis (infection of bone)
Renal failure (kidney dysfunction)
Subdural hygroma (subdural collection of cerebrospinal fluid (csf), without blood)

60+:

Tumour flare (temporary increase in symptoms from a cancer after starting treatment)
Aggression
International normalised ratio increased
Rash generalised (rash on most of body parts)
Respiratory failure (inadequate gas exchange by the respiratory system)
Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)
Vasoplegia syndrome (low systemic vascular resistance)
Agitation (state of anxiety or nervous excitement)
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Anxiety

What are the existing conditions these people have? *

Gastritis (inflammation of stomach): 19 people, 61.29%
Dyslipidaemia (abnormal amount of lipids): 19 people, 61.29%
Device Related Infection: 15 people, 48.39%
Pain: 3 people, 9.68%
Urinary Retention (the inability to completely or partially empty the bladder): 2 people, 6.45%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 6.45%
Laxative Supportive Care: 2 people, 6.45%
High Blood Cholesterol: 2 people, 6.45%
Gastrointestinal Motility Disorder (abnormal intestinal contractions): 2 people, 6.45%
Gastrointestinal Infection (infection of stomach and intestine): 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Azactam and Haldol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously